Advertising
Showing 1 to 13 of 13 entries
  • «
  • 1
  • »
BUY
It hit a new 52-week high today, based on it successful Covid treatment that gets patients out of the hospital a lot faster.
Pharma & Healthcare

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
PAST TOP PICK
(A Top Pick Nov 24/20, Up 22.3%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with REGN has achieved its $630 objective. To be disciplined, we recommend covering 50% of the position and trailing up the stop (from $425) to $565.
Pharma & Healthcare
COMMENT
They developed a Covid treatment drug, but Washington has been unkind to them and made it inaccessible to the public. A great company, but it can't work for free.
Pharma & Healthcare
HOLD
It confuses him. They produce great drugs and are run by a fine CEO, but they aren't making a lot of money on their Covid cocktail. The stock has been struggling, but he would not sell.
Pharma & Healthcare
BUY on WEAKNESS
Buy it under $500. It hasn't been in the news lately. They have a great Covid drug, but aren't making enough of it.
Pharma & Healthcare

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
TOP PICK
Stockchase Research Editor: Michael O'Reilly REGN’s COV2 antibody treatment used by the US President during his treatment has been granted Emergency Use Authorization by the FDA. Even though vaccine alternatives are coming, this will provide treatment options for those infected and will help reduce hospitalizations. We would buy this with a $425 stop-loss looking to achieve $630 – 21% upside. Yield 0% (Analysts’ price target is $628.52)
Pharma & Healthcare
PAST TOP PICK
(A Top Pick Jul 17/19, Up 95%) They've developed an antibody for Covid. Great company that he's been adding to. Fine valuation. They have a fine franchise in a severe atopic dermatitis drug. They're also developing an asthma drug that looks promising.
Pharma & Healthcare
BUY
Just announced that their new drug cocktail can treat Covid immediately upon testing positive. The stock actually went down today, but he's been recommending this for a while.
Pharma & Healthcare
TOP PICK
A higher-risk/return play. This biotech has several core products generating good free cash flow. They’re partnering with Sanofi on Dupixent to treatment severe atopic dermatitis and potentially severe asthma. They also have another drug to treat specific eye diseases. REGN boasts various late-stage drug trials. Regeneron is a new Top Pick for us, driven by the valuation having compressed significantly on concerns over U.S. Medicare Part B drug pricing policy proposals. We believe these are more than reflected in the current price.Their dermatitis drug is getting traction. This stock has been beat up for the wrong reasons. This (Analysts’ price target is $389.38)
Pharma & Healthcare
BUY
Diversity is key. Large biotech has been beat up. Speculation that Novartis is a competitor, but it's at early stages for them. REGN does have a drug for a niche market. Correction is in part because of Novartis speculation plus medicare reimbursement. Current multiple around 13x, you can buy it, but buy it in a basket.
Pharma & Healthcare
PAST TOP PICK

(Past Top Pick on August 8, 2017, Down 40%) Sold his at a stop loss before things got worse. You must be ruthless in selling your losers or you'll suffer even more downside.

Pharma & Healthcare
TOP PICK

He likes biotech as a space, and it has recently re-accelerated. This company has a number of key drugs. Their major drug is Eylea for macular degeneration, a multi-, multi-billion-dollar drug. However, they have a newer drug, which is aimed at the allergy market, which could potentially be a $10 billion drug. This company will double its earnings in the next 3 years and is not dependent on one product. (Analysts’ price target is $438.)

Pharma & Healthcare
HOLD

Loves the biotech sector right now. If he had to invest money in one sector right now, it would be Biotechs. He likes this company. They are positioned very well.

Pharma & Healthcare
Showing 1 to 13 of 13 entries
  • «
  • 1
  • »

Regeneron Pharmaceuticals Inc(REGN-Q) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 5

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 6

Stockchase rating for Regeneron Pharmaceuticals Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Regeneron Pharmaceuticals Inc(REGN-Q) Frequently Asked Questions

What is Regeneron Pharmaceuticals Inc stock symbol?

Regeneron Pharmaceuticals Inc is a American stock, trading under the symbol REGN-Q on the NASDAQ (REGN). It is usually referred to as NASDAQ:REGN or REGN-Q

Is Regeneron Pharmaceuticals Inc a buy or a sell?

In the last year, 6 stock analysts published opinions about REGN-Q. 5 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Regeneron Pharmaceuticals Inc.

Is Regeneron Pharmaceuticals Inc a good investment or a top pick?

Regeneron Pharmaceuticals Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Regeneron Pharmaceuticals Inc.

Why is Regeneron Pharmaceuticals Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Regeneron Pharmaceuticals Inc worth watching?

6 stock analysts on Stockchase covered Regeneron Pharmaceuticals Inc In the last year. It is a trending stock that is worth watching.

What is Regeneron Pharmaceuticals Inc stock price?

On 2021-09-22, Regeneron Pharmaceuticals Inc (REGN-Q) stock closed at a price of $643.72.